UY32189A - Ligandos que tienen esepecificidad de unión por dc-sign - Google Patents

Ligandos que tienen esepecificidad de unión por dc-sign

Info

Publication number
UY32189A
UY32189A UY0001032189A UY32189A UY32189A UY 32189 A UY32189 A UY 32189A UY 0001032189 A UY0001032189 A UY 0001032189A UY 32189 A UY32189 A UY 32189A UY 32189 A UY32189 A UY 32189A
Authority
UY
Uruguay
Prior art keywords
sign
immunoglobulins
compositions
esepecificity
ligandos
Prior art date
Application number
UY0001032189A
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Mari De Wildt
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of UY32189A publication Critical patent/UY32189A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
UY0001032189A 2008-10-21 2009-10-20 Ligandos que tienen esepecificidad de unión por dc-sign UY32189A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21

Publications (1)

Publication Number Publication Date
UY32189A true UY32189A (es) 2010-05-31

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032189A UY32189A (es) 2008-10-21 2009-10-20 Ligandos que tienen esepecificidad de unión por dc-sign

Country Status (16)

Country Link
US (1) US20110257373A1 (enExample)
EP (1) EP2356149A2 (enExample)
JP (1) JP2012506237A (enExample)
KR (1) KR20110071139A (enExample)
CN (1) CN102257009A (enExample)
AR (1) AR073905A1 (enExample)
AU (1) AU2009306424A1 (enExample)
BR (1) BRPI0919714A2 (enExample)
CA (1) CA2740856A1 (enExample)
EA (1) EA201100488A1 (enExample)
IL (1) IL212086A0 (enExample)
MX (1) MX2011004244A (enExample)
TW (1) TW201019962A (enExample)
UY (1) UY32189A (enExample)
WO (1) WO2010046337A2 (enExample)
ZA (1) ZA201102763B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009306425B2 (en) * 2008-10-21 2013-09-12 Domantis Limited Composition for targeting dendritic cells
EP2793918B1 (en) * 2011-12-19 2019-09-11 The Rockefeller University Hdc-sign binding peptides
EP4392022A4 (en) * 2021-08-27 2025-11-12 Univ Georgia Targeted Nanoparticles and Their Uses in Infectious Disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665440B2 (en) * 1992-06-05 1996-01-04 Dade Produktions Ag Rabbit single domain antibody and use thereof
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
US20090005257A1 (en) * 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
SI1639011T1 (sl) * 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
CN1893925B (zh) * 2003-08-21 2011-04-27 利普泰克有限公司 树突细胞的体内靶向
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
BRPI0518761A2 (pt) * 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
WO2006097689A2 (en) * 2005-03-18 2006-09-21 Domantis Limited Antibodies against candida antigens
TW200804425A (en) * 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
CA2632424A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
TW200804593A (en) * 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
US20100143371A1 (en) * 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
KR20110071139A (ko) 2011-06-28
JP2012506237A (ja) 2012-03-15
CN102257009A (zh) 2011-11-23
BRPI0919714A2 (pt) 2015-12-08
MX2011004244A (es) 2011-05-25
CA2740856A1 (en) 2010-04-29
AR073905A1 (es) 2010-12-09
WO2010046337A3 (en) 2010-07-01
EA201100488A1 (ru) 2011-12-30
WO2010046337A2 (en) 2010-04-29
IL212086A0 (en) 2011-06-30
US20110257373A1 (en) 2011-10-20
EP2356149A2 (en) 2011-08-17
ZA201102763B (en) 2012-09-26
AU2009306424A1 (en) 2010-04-29
TW201019962A (en) 2010-06-01

Similar Documents

Publication Publication Date Title
CL2015001507A1 (es) Proteínas de unión al antígeno bcma
ZA202308845B (en) Cx3cr1-binding polypeptides
CY1121560T1 (el) Ανοσογονικη συνθεση
CO6361953A2 (es) Fusiones y conjugados de fármaco
BR112014023415A2 (pt) moléculas que se ligam a ang2
UA116632C2 (uk) Химерний білок, який містить фактор viii та фактор віллебранда, і його застосування
CR9969A (es) Anticuerpos anti-globulomero ab, porciones de union a antigeno de estos, hibridomas correspondientes, acidos nucleicos, vectores, celulas huesped, metodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos
UY33588A (es) Moleculas de union a vegf
UA114707C2 (uk) БІСПЕЦИФІЧНА ЗВ'ЯЗУВАЛЬНА МОЛЕКУЛА, ЯКА ЗВ'ЯЗУЄТЬСЯ З VEGF I Ang2
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
JOP20170027B1 (ar) بنيات جسم مضاد مشتبك بخلية t ثنائي الانتقائية لـ bcma وcd3
EA201791744A2 (ru) Улучшенная липидная композиция
BR112014028645A2 (pt) composições e métodos para modulação da expressão de apoa1 e abca1.
RU2014136702A (ru) Одноцепочечные антитела и другие гетеромультимеры
IN2012DN00640A (enExample)
IL211394B (en) Chimeric fusion proteins for inducing an immune response to p. gingivalis, preparations containing them and their uses
EA201590209A1 (ru) Применение cart19 для истощения нормальных b-клеток для индукции толерантности
BR112015021838A2 (pt) amatoxina, método de síntese, composição farmacêutica
WO2011086143A3 (en) Liver targeting domain antibodies
BR112022010627A2 (pt) Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados
WO2012009544A3 (en) Domain insertion immunoglobulin
EA201590887A1 (ru) Композиция
MX380778B (es) Compuestos y métodos para la modulación de expresion de proteína cinasa de distrofia miotónica (dmpk).
BR112016012627A2 (pt) composições compreendendo um polipeptídeo de beta-glicosidase e métodos de uso
AR073905A1 (es) Ligandos que tienen especificidad de union por dc-sign